glp 1 agonist classification of 1R Agonists Glucagon-like peptide-1 receptor agonists(GLP-1RAs)** GLP-1

The more people use an expensive drug, the bigger the impact it has on the entire health insurance market

Article highlights - GLP-1 receptor agonists cause gastrointestinal symptoms, but these effects do not usually cause discontinuation of therapy

In addition to the effect on food intake reduction and glucose-stimulated insulin secretion, GLP-1 also acts to delay gastric emptying therefore aiding satiety and glycaemic control (42)

Our analysis also confirms that GLP-1RA, when compared with placebo, reduce the risk of MACE, total death, HHF, and the composite renal outcome [12]

Also, other contributing factors, such as raised R&D activities, the development of oral formulations, and the potential for accelerated therapeutic applications, are driving the market growth

Orforglipron Orforglipron (Eli Lilly) is a novel oral GLP-1 receptor agonist that is currently in phase 3 clinical trials